Clair Health Raises $11.6M Seed to Bring Continuous Hormone Monitoring Into the Wearable Era

Clair Health, a San Francisco-based femtech and wearable biosensing startup, has raised $11.6M in seed funding led by Khosla Ventures, with participation from Brydge Club, Cartan Capital, AGI House, Insiders VC, and 23andMe co-founder Anne Wojcicki.

The company is developing a wearable platform designed to provide continuous, noninvasive hormone monitoring for women. Clair says its technology is built to track hormones including estrogen, progesterone, LH, FSH, and PdG while combining those signals with broader physiological data.

The funding will support clinical research, product development, validation efforts, and commercialization as Clair moves toward launch. The broader implication extends beyond a single startup. Investors are increasingly backing technologies that transform previously invisible biological signals into measurable, actionable data, placing Clair Health at the intersection of femtech, wearable computing, biosensing, and machine learning.

What Happened

The wearable industry has spent more than a decade turning the human body into a stream of dashboards. Steps became data. Sleep became data. Recovery became data. Heart rate variability became data. Hormones largely remained outside that transformation.

That gap is what Clair Health is attempting to address. Founded in 2025, Clair Health announced an $11.6M seed round led by Khosla Ventures, bringing together a syndicate that includes Brydge Club, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. For an early-stage startup operating in one of healthcare's most technically demanding categories, the investor lineup stands out.

Clair Health was founded by CEO Jenny Duan and CTO Abhinav Agarwal, who are building a wrist-worn wearable designed to continuously monitor hormonal changes without relying on traditional testing methods. The company positions its product as a new layer of biological intelligence focused specifically on women's health. While many consumer health products have historically treated female physiology as a secondary use case, Clair Health is building from the opposite direction.

Why This Matters

A surprising amount of modern healthcare still relies on snapshots. A blood test captures a moment. A lab result captures a moment. A hormone panel captures a moment. Human biology does not operate in moments.

Hormones fluctuate continuously, influencing fertility, recovery, athletic performance, mood, sleep quality, energy levels, and broader health outcomes. Yet obtaining meaningful hormone data often requires expensive testing, inconvenient collection methods, or infrequent measurements that miss the larger story. According to the company, Clair Health's platform combines wearable sensors, machine learning, and physiological monitoring to generate continuous hormonal insights.

Clair says its system captures more than 130 biomarkers across multiple biological domains and uses models trained against clinical-grade hormone measurements. Healthcare increasingly rewards visibility, and the more biological systems become measurable, the more opportunities emerge for preventative care, personalized health management, and informed decision-making. Investors are effectively betting that hormones represent one of the next major categories to become continuously monitored.

Market Context

The timing of Clair Health's funding round reflects broader trends across both healthcare and venture capital. Clair Health operates within the rapidly growing femtech and digital health sector, a category attracting increased venture investment across fertility, menopause, diagnostics, and personalized health monitoring. Across the market, investors continue searching for large healthcare opportunities that have historically received limited innovation investment.

At the same time, wearable technology continues expanding beyond activity tracking. The first generation of wearables focused on movement. The second focused on cardiovascular metrics. The next wave is moving deeper into biological systems that were previously difficult to measure outside clinical environments, attracting venture firms looking for large and defensible markets.

Khosla Ventures has a history of investing in healthcare, life sciences, and deep technology companies pursuing technically ambitious problems. Clair Health aligns closely with that investment thesis. The startup is headquartered in San Francisco, one of the world's most influential ecosystems for venture-backed healthcare and technology companies.

Competitive Landscape

Clair Health is entering a market filled with both opportunity and complexity. The wearable health ecosystem already includes companies focused on sleep tracking, metabolic monitoring, cardiovascular health, recovery metrics, and fertility management. Continuous hormone intelligence remains a comparatively underdeveloped category.

That distinction creates both potential advantages and substantial technical hurdles. Building healthcare hardware capable of continuously inferring hormonal changes combines engineering, biosensing, clinical validation, machine learning, consumer adoption, and regulatory considerations into a single challenge. Few startup categories require simultaneous excellence across so many disciplines.

Clair Health's ability to execute will ultimately depend not only on technological performance but also on clinical credibility and consumer trust. The company has already reported that its first 5,000 Founding Member spots sold out, offering an early indication of market interest ahead of broader commercial availability.

What This Signals

Strong funding rounds often reveal investor beliefs before they reveal market outcomes. The Clair Health announcement signals growing confidence in continuous biological monitoring, women's health innovation, and the expansion of wearable technology into areas traditionally associated with clinical measurement.

The venture market has become significantly more selective in recent years. Capital is no longer flowing simply because a startup occupies a fashionable category. Investors increasingly look for technical depth, meaningful market opportunities, and the potential to build defensible businesses.

Clair Health's ability to attract a syndicate led by Khosla Ventures suggests experienced investors believe the opportunity is worth pursuing. Funding alone does not determine outcomes, but it does reveal where sophisticated capital sees potential asymmetry.

The Bigger Industry Shift

A larger transformation is unfolding across healthcare. For decades, medicine largely operated as a system built around intermittent measurement. The future increasingly points toward continuous measurement.

Wearables, sensors, machine learning models, and mobile computing are creating an environment where biological changes can be observed with far greater frequency than traditional healthcare systems were designed to support. That does not eliminate the need for physicians, diagnostics, or clinical expertise, but it does create opportunities for earlier awareness, richer context, and more informed conversations.

Clair Health's funding round represents another step toward that future. The company still faces the difficult work of proving its technology, scaling operations, and delivering on ambitious goals. Yet the financing reflects a growing belief that hormone monitoring may eventually become as familiar as heart-rate tracking is today.